Non-exclusive drug discount agreement for Naproxen (excluding syrup)
Titre original de l'avis
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naproxen exklusive der Darreichung Sirup (ATC-Code nach WHO: M01AE02)
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
20 / 100
Facteurs de risque
No minimum purchase quantities; actual demand depends on prescription and pharmacy behavior. Revenue is entirely specul...
The buyer can terminate the Open-House model early if exclusive agreements are made, which typically happens 8-12 month...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Strong opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Aug 2028
- Supply of Naproxen (excluding syrup) pharmaceutical products
- Conclusion of non-exclusive discount agreements with AOK PLUS
Afficher le résumé complet
This is a non-exclusive drug discount agreement (Rabattvereinbarung) under an Open-House model for the active substance Naproxen (excluding syrup), organized by AOK PLUS for the regions Saxony and Thuringia. The agreement is open to all interested pharmaceutical companies that meet the participation requirements. No minimum purchase quantities are guaranteed, and the contract ends at the latest on 31.08.2028. The procedure is not a classic public procurement but a voluntary publication for transparency.
Risques
No minimum purchase quantities; actual demand depends on prescription and pharmacy behavior. Revenue is entirely specul...
The buyer can terminate the Open-House model early if exclusive agreements are made, which typically happens 8-12 month...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Must be a pharmaceutical company as per § 4 Abs. 18 AMG for the offered products
- Company must have its seat in Germany, EU, or EEA
Eligibility
- Declaration of no exclusion grounds (§§ 123, 124 GWB) required
Les exigences peuvent être incomplètes.
Acheteur
Localisation
Erfurt, DEU
Site web
Profil acheteur
Identifiant
DE256878834
Activité
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Naproxen (excluding syrup)
Conclusion of non-exclusive discount agreements for Naproxen (excluding syrup) under an Open-House model. The contract ends at the latest on 31.08.2028. No exclusivity, no minimum purchase quantities.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Siehe Kurzbeschreibung
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naproxen exklusive der Darreichung Sirup (ATC-Code nach WHO: M01AE02)
Description TED originale
Siehe Kurzbeschreibung
Détails de la procédure
- Date de publication
- 30 Jun 2026
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 451272-2026
Documents (1)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
20 / 100
Facteurs de risque
No minimum purchase quantities; actual demand depends on prescription and pharmacy behavior. Revenue is entirely specul...
The buyer can terminate the Open-House model early if exclusive agreements are made, which typically happens 8-12 month...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications